Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HB55
UPID:
CP343_HUMAN
Alternative names:
-
Alternative UPACC:
Q9HB55; Q495Y1; Q75MK2; Q75MK3; Q9HB52; Q9HB53; Q9HB54; Q9HB57
Background:
Cytochrome P450 3A43, encoded by the gene with accession number Q9HB55, plays a crucial role in the metabolism of various substances within the body. It exhibits low testosterone 6-beta-hydroxylase activity, indicating its involvement in the modification of testosterone, a key hormone in human physiology.
Therapeutic significance:
Understanding the role of Cytochrome P450 3A43 could open doors to potential therapeutic strategies. Its involvement in hormone metabolism suggests its potential impact on diseases related to hormonal imbalances.